Please enter exact key words
Antibody-drug Conjugates (ADC) Against GPR20

for the Treatment of Gastrointestinal Stromal Tumor

Home / Available Projects / Antibody-drug Conjugates (ADC) Against GPR20

Antibody-drug Conjugates (ADC) Against GPR20

Drug Name GPCR-targeted Project 010

G protein-coupled receptor 20 (GPR20) is an orphan GPCR. GPR20 expression is regulated by FOXF1 and ETV1 transcription factors that play critical roles in KIT-driven initiation, proliferation, and survival of gastrointestinal stromal tumor.
An antibody-drug conjugate (ADC) is being developed for the treatment of gastrointestinal stromal tumor. This ADC is comprised of a monoclonal antibody that targets the GPR20 antigen and a topoisomerase I inhibitor payload. In vitro studies, the candidate showed anti-tumor activity in GPR20 expressing tumor cells.

Target G-protein coupled receptor 20 (GPR20)
Drug Modality Antibody-drug conjugate
Indication Gastrointestinal stromal tumor
Product Category Biologic
Mechanism of Action DNA topoisomerase I inhibitors
Status Discovery
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.